Maya Savira

Maya Savira

Auto-generated profile, based on publicly available information

Maya Savira

Department of Microbiology, Faculty of Medicine, Universitas Riau, Pekanbaru, Indonesia

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2023 in F1000Research
Verified
Journal Article
Open access
PDF file
DSDonel S
Donel S
DNDhini Aiyulie Novri
Dhini Aiyulie Novri
YHYulis Hamidy
Yulis Hamidy
MSMaya Savira
Maya Savira
Background: Preeclampsia is a highly prevalent disease among pregnant women. In the event of hypertensive emergency, nifedipine, labetalol, and hydralazine are assigned as first-line therapies in preeclampsia. Further studies are needed to compare the effectiveness of these drugs to find the most cost-effective drug with minimal side effects. This study aimed to compare the effectiveness of these drugs in lowering blood pressure during hypertensive emergencies in severe preeclampsia. Methods: 60 pregnant women with severe preeclampsia were recruited in this multiple centre double-blind randomized clinical trial from May 2021 to April 2022 in Indonesia. The patients were divided equally into three groups and treated with three doses of nifedipine, labetalol, and hydralazine, respectively within one hour with 20 minutes interval. The effectiveness was measured based on systolic and diastolic blood pressures, and mean arterial pressure (MAP). The observation was carried out until five hours post-third dose administration. Results: The blood pressure was reduced significantly after the administration of the first to the third dose of each antihypertensive (plabetalol>hydralazine (57.49%, 42.13%, and 40.87%, respectively) for single dose and hydralazine>nifedipine>labetalol (111.3%, 85.12%, and 90.04%, respectively) for triple dose. Conclusions: Nifedipine is the most effective drug to reduce the blood pressure when single dose administration is used, but requires more doses to further reduce the blood pressure. Hydralazine is the most effective when the drug administration is maxed up to three doses within 60 minutes with 20 minutes interval. Thai Clinical Trials Registry (TCTR): TCTR20221014007 (14/10/2022)

1 March 2018 in Majalah Kedokteran Bandung
Verified
Journal Article
Open access
PDF file
DADewi Anggraini
Dewi Anggraini
UYUtari Gusti Yulindra
Utari Gusti Yulindra
MSMaya Savira
Maya Savira
FDFauzia Andrini Djojosugito
Fauzia Andrini Djojosugito
NHNopian Hidayat
Nopian Hidayat
Resistensi antimikrob merupakan salah satu masalah kesehatan masyarakat yang besar yang dihadapi manusia sejak era ditemukan antimikrob. Angka multidrug resistant P. aeruginosa salah satunya semakin meningkat di berbagai belahan dunia yang berdampak pada kesulitan penanganan infeksi oleh bakteri ini. Penelitian deskriptif retrospektif ini bertujuan mengetahui prevalensi MDR P.aeruginosa dan pola sensitivitasnya. Data diambil dari hasil kultur bakteri dan uji resistensi antibiotik dari berbagai spesimen klinis pasien di RSUD Arifin Achmad sepanjang tahun 2015. Uji resistensi dilakukan dengan menggunakan alat Vitek 2 compact. MDR P. aeruginosa didefinisikan sebagai P. aeruginosa yang tidak sensitif terhadap tiga atau lebih golongan antibiotik berikut: meropenem atau imipenem, siprofloksasin, gentamisin atau amikasin, seftazidim atau sefepim, dan piperasilin/tazobaktam. Prevalensi MDR P. aeruginosa adalah 45,5%. Isolat MDR P. aeruginosa serta paling banyak berasal dari instalasi perawatan surgikal dan instalasi perawatan intensif, dan paling banyak berasal dari spesimen pus dan sputum. Sensitivitas P. aeruginosa paling baik dengan amikasin (76,9%), piperasilin/tazobaktam (57,2%), meropenem (57,0%), gentamisin (54,5%), sefepim (53,7%), seftazidim (49,6%), ciprofloksasin (48,8%) dan aztreonam (35,5%). Sensitivitas MDR P.aeruginosa terhadap antibiotik jauh lebih rendah dibanding dengan P. aeruginosa. Penelitian ini menunjukkan angka MDR P. aeruginosa tinggi khususnya di Pekanbaru. Pola sensitifas P. aeruginosa dapat menjadi pedoman dalam memilih antibiotik yang sesuai untuk infeksi karena P. aeruginosa.Kata kunci: Multidrug resistant, Pekanbaru, pseudomonas aeruginosa, sensitivitas antibiotik Prevalence and Antimicrobial Susceptibility Profile of Multidrug Resistant Pseudomonas aeruginosa in Arifin Achmad General HospitalAntimicrobial resistance is one of major public health problems since the era of antimicrobial discovery, inclusing multidrug resistant (MDR) P. aeruginosa. The prevalence of this resistance is increasing in different parts of the world, leading to the difficulties in dealing with this bacteria. The aim of this descriptive retrospective study was to determine the prevalence of MDR P. aeruginosa and its susceptibility profile. Data were collected from the bacteria cultures and antibiotic susceptibility test results from various clinical specimens in Arifin Achmad General Hospital throughout 2015. The test was performed in VITEK 2 Compact. MDR P. aeruginosa is defined as P. aeruginosa which is not sensitive to three or more following antibiotics: meropenem or imipenem, ciprofloxacin, gentamicin or amikacin, ceftazidime or cefepime, and piperacilin/tazobactam. The prevalence of MDR P. aeruginosa was 45.5%. The isolates of MDR P. aeruginosa was mostly derived from pus and sputum specimens from the surgical ward and intensive care unit. . The most sensitive antibiotics was amikacin (76.9%) followed by piperacilin/tazobactam (57.2%), meropenem (57.0%), gentamicin (54.5%), cefepime (53.7%), ceftazidime (49.6%), ciprofloxacin (48.8%), and aztreonam (35.5%). Antibiotic sensitivity in MDR P. aeruginosa was much lower than in P. aeruginosa. This study shows a high prevalence of MDR P. aeruginosa, especially in Pekanbaru. This susceptibility profile can serve as a guideline for the selection of appropriate antibiotics for infections caused by P. aeruginosa.Key words: Antibiotic susceptibility, multidrug resistant, Pekanbaru, pseudomonas aeruginosa

21 April 2025 in Narra J
Verified
Journal Article
Open access
PDF file
MSMaya Savira
Maya Savira
AFAnaldi Farniga
Analdi Farniga
ZIZidny Ilmiah
Zidny Ilmiah
RRRachmadina Rachmadina
Rachmadina Rachmadina
IRIka Agus Rini
Ika Agus Rini
APAndani E. Putra
Andani E. Putra
The L2 protein, a minor capsid component of human papillomavirus (HPV), plays a critical role in the HPV life cycle by packaging the viral genome with the L1 protein and facilitating DNA transport to the nucleus. Identifying genetic variations in the L2 gene is essential for improving vaccine development, diagnostic accuracy, and understanding viral evolution, potentially contributing to more effective HPV vaccines. The aim of this study was to investigate the genetic variation of the L2 gene in cervical cancer specimens collected from patients in Riau Province, Indonesia. A single-center, cross-sectional study was conducted at Arifin Achmad General Hospital, Riau Province, involving cervical cancer patients with confirmed HPV16 infection between January 2018 and August 2020. Demographic, clinical, and risk factor data were collected through structured interviews and direct assessments. Cervical biopsy specimens were collected, and viral DNA was extracted for L2 gene amplification using polymerase chain reaction (PCR). Sequencing was conducted on PCR products, followed by single-nucleotide polymorphism (SNP) identification through alignment with the HPV16 reference genome. The amplification and sequencing of the HPV16 L2 gene from 22 cervical cancer specimens revealed 36 SNPs, including 31 nonsynonymous and five synonymous mutations. High-frequency mutations were observed at nucleotide positions 4,074 and 4,177, each detected in 95.45% of the samples. Notable insertions were found at positions 3,668–3,669 and 4,275–4,276, indicating substantial sequence variation. Phylogenetic analysis grouped the sequences into three clusters, with most belonging to sub-lineage A2 (European), while others aligned with A4 (Asian) and East Asian lineages. The observed genetic diversity in the HPV16 L2 gene may reflect regional viral evolution and has potential implications for future vaccine development.

27 August 2024 in Narra J
Verified
Journal Article
Open access
PDF file
NPNurfi Pratiwi
Nurfi Pratiwi
AUAida J. Ulfah
Aida J. Ulfah
RRRachmadina Rachmadina
Rachmadina Rachmadina
Lalu Muhammad IrhamLalu Muhammad Irham
Lalu Muhammad Irham
AAArief R. Afief
Arief R. Afief
MSMaya Savira
Maya Savira
Cervical cancer is the fourth most common cancer among women globally, and studies have shown that genetic variants play a significant role in its development. A variety of germline and somatic mutations are associated with cervical cancer. However, genomic data derived from these mutations have not been extensively utilized for the development of repurposed drugs for cervical cancer. The objective of this study was to identify novel potential drugs that could be repurposed for cervical cancer treatment through a bioinformatics approach. A comprehensive genomic and bioinformatics database integration strategy was employed to identify potential drug target genes for cervical cancer. Using the GWAS and PheWAS databases, a total of 232 genes associated with cervical cancer were identified. These pharmacological target genes were further refined by applying a biological threshold of six functional annotations. The drug target genes were then cross-referenced with cancer treatment candidates using the DrugBank database. Among the identified genes, LTA, TNFRSF1A, PRKCZ, PDE4B, and PARP were highlighted as promising targets for repurposed drugs. Notably, these five target genes overlapped with 12 drugs that could potentially be repurposed for cervical cancer treatment. Among these, talazoparib, a potent PARP inhibitor, emerged as a particularly promising candidate. Talazoparib is currently being investigated for safety and tolerability in other cancers but has not yet been studied in the context of cervical cancer. Further clinical trials are necessary to validate this finding and explore its potential as a repurposed drug for cervical cancer.

1 September 2018 in Malaysian Journal of Microbiology
Verified
Journal Article
Open access
SMS. Maya
S. Maya
AFA.D. Fauzia
A.D. Fauzia
ADA. Dewi
A. Dewi
EAE.P. Andani
E.P. Andani

1 June 2009 in Majalah Kedokteran Bandung
Verified
Journal Article
Open access
PDF file
DSDonel Suhaimi
Donel Suhaimi
MSMaya Savira
Maya Savira
SKSofie R. Krisnadi
Sofie R. Krisnadi
Acquired immunodeficiency syndrome (AIDS) adalah penyakit yang disebabkan oleh infeksi virus human immunodeficiency virus (HIV). AIDS dikarakteristikkan sebagai penyakit imunosupresif berat yang sering dikaitkan dengan infeksi oportunistik dan tumor ganas serta degenerasi susunan saraf pusat. Penyebaran HIV ini berkembang dengan cepat dan mengenai wanita dan anak-anak. AIDS menyebabkan kematian lebih dari 20 juta orang setahun. Tahun 2003 diperkirakan 700.000 bayi baru lahir terinfeksi HIV di seluruh dunia. Angka morbiditas dan mortalitas yang disebabkan oleh HIV semakin meningkat dan merupakan masalah kesehatan masyarakat yang paling penting di semua negara. Penggunaan obat antivirus seperti highly active antiretroviral therapy (HAART) dan persalinan berencana dengan seksio sesaria telah menurunkan angka transmisi perinatal mother to child trasmission (MTCT) penyakit ini dari 30% menjadi 20%. Manejemen antenatal, persalinan, dan perawatan pascasalin yang terkontrol dengan baik pada ibu hamil dengan HIV dapat mencegah transmisi perinatal. Kata kunci : AIDS, HAART, MTCT PREVENTION AND MANAGEMENT OF HIV INFECTION (AIDS) IN PREGNANCY Acquired immunodeficiency syndrome (AIDS) is a disease which caused by human immunodeficiency virus (HIV). Characteristic of AIDS is due to severe immunosupresive disease which related to opportunistic infection, malignant tumour and central nervous system degeneration. HIV spread widely and mostly infect women and children. Mortality rate of AIDS are more than 20 million people per year. In 2003, 700,000 newborn were infected by HIV in the world. Morbidity and mortality rate of HIV are highly increase dan become an important public health problem in all around the world. Using of antiviral drugs like highly active antiretroviral therapy (HAART) and ceasarean labor has decreased the perinatal transmission (mother-to-child trasmission=MTCT) rate of this disease from 30% to 20%. The intensive control in management of antenatal care, labor and delivery for the pregnant women with HIV can prevent the perinatal transmission. Key words: AIDS, HAART, MTCT DOI: http://dx.doi.org/10.15395/mkb.v41n2.184